Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + VRD vs VRD in high-risk, transplant-ineligible newly diagnosed multiple myeloma
ChiCTR2600116772Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: MRD negative rate at 12 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2600116772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116772.